More numbers and types of standard cells increased the validation of new drug.

Dear Juma Almutaani

You are right. The answer is NO. I would like to add further.

At least three different cell lines representing various cell types and tissue origins will be required. For instance,

- Some drugs may have specific targets in certain cell types, so using a panel of cell lines allows for a broader assessment of potential effects. If the drug is intended for a specific disease, cell lines derived from that disease (for example, cancer cell lines for an anticancer drug) are crucial.

- Different cell lines may exhibit varying metabolic capabilities, impacting how they process the drug and its potential toxicity. Cell lines with different metabolic capabilities can help identify potential metabolic pathways that might be affected by the drug.

- Finally, use of normal cell lines would be important for assessing safety of the new drug.

You may also go beyond cell lines and try cell-free systems like NMR and X-ray crystallography which can provide valuable information about drug interactions. After conducting in vitro studies, in vitro findings may be validated in animal models (in vivo) before clinical trials.

Regards,

Malcolm Nobre

Very clear explanation with many thanks Malcolm Nobre

No, one cell line is not enough to study the cytotoxicity of a new drug; different cell types can respond differently due to variations in genetics, metabolism, and tissue origin. Using multiple cell lines ensures a more accurate and reliable assessment of the drug’s cytotoxicity and potential therapeutic range.

Good evening

I think it would be better to have at least two different cell lines.

A single cell line is not sufficient to assess the drug's cytotoxicity due to variations in genetics, metabolism and tissue origin.

Question: Is one cell line enough to study the cytotoxicity of a new drug?

Answer: No, using only one cell line is not sufficient to comprehensively study the cytotoxicity of a new drug.

Justification:

Biological Diversity: Different cell lines represent different tissue types, genetic backgrounds, and molecular characteristics. A drug might appear non-toxic in one cell type but could be highly toxic or ineffective in another.

Pharmacological Relevance: To mimic the clinical behavior of a chemotherapeutic agent, it's essential to test across multiple cancer cell lines (e.g., colon, breast, lung, etc.) and compare with normal (non-cancerous) cell lines to evaluate selectivity.

Pharmacodynamic and Pharmacokinetic Considerations:

Pharmacodynamics: Testing in multiple lines helps determine variations in drug response, including IC₅₀ values and apoptotic induction.

Pharmacokinetics: Cellular uptake, metabolism, and efflux can differ among cell types, influencing observed toxicity.

Regulatory and Scientific Standards: Most peer-reviewed journals and regulatory guidelines (like those from the FDA or EMA) require multi-cell line testing to ensure data validity and reproducibility.

Conclusion:

For robust and reliable cytotoxicity assessment of a new drug, it is standard practice to use a panel of cell lines, including both cancerous and non-cancerous types, to capture a broad spectrum of biological responses.

Thank you, Mr. Hezam, for the generous information. Well done.

Perhaps also consider testing in brine shrimp as a toxicity model on an organism rather than just a cell line. It's easy and cheap and can give you a good idea about metabolic transformation. Also consider after your cell line assays to extract and quantify your free drug to get information about metabolism---get as much information from the treated cells as you can before you discard them to save time later. Good luck,

The brine shrimp model is a significant consideration. Thanks, Dr Michael Coote.